| Document |
Document Title |
|
WO/2015/053797A2 |
The present invention relates to novel synthetic aspirin-mimics that mimic the molecular structure of aspirin, with sulfur to replace oxygen in the key functional groups of aspirin. The novel synthetic aspirin-mimics in this invention in...
|
|
WO/2015/051141A1 |
Methods for preparing fluorinated sulfides and fluorinated sulfones are described. To prepare a fluorinated sulfides, a sulfur-containing reactant represented by the formula: R1SM or M2S, wherein R1 is a C1 to C10 alkyl or fluoroalkyl, S...
|
|
WO/2015/039935A1 |
The invention relates to a process for crystallizing D,L-methionine from aqueous solutions and/or suspensions containing D,L-methionine and D,L-methionine ammonium salts and having a Met content of 70-180 g/kg, an NH4 + content of 1-5 g/...
|
|
WO/2015/035003A1 |
Disclosed are inhibitors of retroviral growth of formula (I), that are useful in treatment of retroviral infections such as HIV. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound ...
|
|
WO/2015/033936A1 |
The present invention relates to a polyarylene sulfide resin manufacturing method comprising: a process for obtaining a poly(arylene sulfonium salt) having specified constituent units by reacting a sulfoxide represented by general formul...
|
|
WO/2015/027833A1 |
The present invention relates to compounds represented by general formulas I, IIa, lib and III and preparation method therefor. Ar1 is substituted o-arylene or o-heteroarylene; Ar2 is bis(o-arylene) or bis(o-heteroarylene) connected in v...
|
|
WO/2015/028766A1 |
The invention relates to new α-vinyl carbonylated compounds corresponding to general formula (I), wherein R1, R2, R3, R4, R5 and Y are as defined in claim 1, their isomers, their diastereoisomers and acid addition salts or a pharmaceuti...
|
|
WO/2015/026601A2 |
Provided are dithiol mucolytic agents. These agents increase the liquefaction of mucus in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties. Also provided are a variety of methods of tr...
|
|
WO/2015/025960A1 |
Provided are: a compound having high activity against harmful organisms; a harmful organism control agent comprising the compound; and a method for controlling harmful organisms by applying the compound. A phenoxyalkylbenzamide-type comp...
|
|
WO/2015/025826A1 |
The purpose of the present invention is to provide: a novel substituted phenyl ether compound which has a control effect against pests; and a pest control agent which contains this substituted phenyl ether compound as an active ingredien...
|
|
WO/2015/011206A1 |
The invention relates to the manufacture of certain polyunsaturated compounds employing a particular application of the Mitsonobu reaction in the presence of at least one anti-oxidant. We have found a method of making a pharmaceutically-...
|
|
WO/2015/001117A1 |
The present invention relates to a process for labeling compounds comprising thiol moieties with 3-arylpropiolonitrile compounds, to 3-arylpropiolonitrile compounds substituted with tag moieties and to specific 3-arylpropiolonitrile link...
|
|
WO/2015/002150A1 |
[Problem] The present invention addresses the problem of providing a novel compound. The present invention also addresses the problem of providing an OCT3 detection agent or an OCT3 activity inhibitor, which comprises the novel compound....
|
|
WO/2014/208284A1 |
The objective of the present invention is to provide: a composition for forming a thermoelectric conversion layer, the composition having exceptional thermoelectric properties; a thermoelectric conversion element in which said compositio...
|
|
WO/2014/203812A1 |
According to the present invention, a composition for an optical material contains a compound (a), a compound (b), and a polyisocyanate compound (c), and can suppress the generation of striae defects. The compound (a) is a compound (1) h...
|
|
WO/2014/197991A1 |
The present application describes amphiphatic compounds like compound Ila below, compositions and methods for incorporating chemoselective and bio-orthogonal complementary functional groups into liposomes. Such compounds are incorporated...
|
|
WO/2014/191535A1 |
The present invention relates to a compound of formula (I): wherein: X is methyl or chlorine; R1 is fluorine or bromine; R2 is ethynyl, C1-C3alkoxy, C1-C3haloalkoxy, or C1-C3alkoxy-C1-C3alkoxy-; and Q is a pyran-3,5-dione-4-yl, a thiopyr...
|
|
WO/2014/191534A1 |
The present invention relates to a compound of formula (I): wherein: X is methyl or chlorine; R1 is fluorine or bromine; R2 is ethynyl, C1-C3alkoxy, C1-C3haloalkoxy, or C1-C3alkoxy-C1-C3alkoxy-; and Q is a pyran-3,5-dione-4-yl, a thiopyr...
|
|
WO/2014/188783A1 |
The purpose of the invention is to provide a production method that makes possible the industrial production of an optically active α-amino acid at high yield and high enantioselectivity, to provide a simple method for producing optical...
|
|
WO/2014/184235A1 |
Compounds of formula I, pharmaceutically acceptable salts thereof, diastereomers, enantiomers, or mixtures thereof: wherein R, X, Y, Z, n and A are as defined in the specification, as well as pharmaceutical compositions including the com...
|
|
WO/2014/178433A1 |
According to the present invention, it becomes possible to perform a process for converting into an α-substituted cysteine represented by general formula (1) or a salt thereof at low cost and on an industrial scale by employing a proces...
|
|
WO/2014/178389A1 |
Provided is a new compound having glycogen synthase activation potency, high muscular transition, minimal activation of receptor PPAR, and a high degree of safety. Provided is a compound represented by the following general formula, or a...
|
|
WO/2014/178381A1 |
Provided is a new compound having glycogen synthase activation potency, but minimal activation of receptor PPAR, and a high degree of safety.　A compound represented by general formula [I], or a pharmaceutically acceptable salt thereof....
|
|
WO/2013/057624A9 |
The present invention relates to a method of treating a parasitic infection in an animal, particularly a filarial endoparasitic infection, comprising administering an effective amount of a Formula (I) compound or a Formula (ll) compound ...
|
|
WO/2014/173839A1 |
A sulphur-comprising polyol compound, usable in particular as a monomer for the synthesis of a polyurethane by polycondensation with a polyisocyanate, corresponding to the formula: (I) HO-Z1-M1-Z3-(M2-Z2)n-OH in which: - Z1 and Z2, which...
|
|
WO/2014/161976A1 |
The present invention provides new intermediate compounds or formulae (III) and (IVa), and salts thereof, and their use in a new synthetic process for the production of 1-(2-((2,4- dimethylphenyl)thio)phenyl)piperazine (vortioxetine) an ...
|
|
WO/2014/148474A1 |
The purpose of the present invention is to provide a defoaming agent with greatly improved defoaming ability, without any adverse effect on surface smoothness, and a surfactant composition, a coating composition, and a resist composition...
|
|
WO/2014/134445A1 |
A compound of formula the following formula:(I). In this formula, moieties A, B, X, R1, R2, and R3 are defined herein. Also disclosed are a nanocomplex that is formed of such a compound and a pharmaceutical agent, and a nanocomplex that ...
|
|
WO/2014/124234A1 |
The present invention relates to alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2014/112646A1 |
The present invention addresses the problem of providing a compound having a selective inhibitory activity on LAT-1 that can be expressed in a tumor cell at a high level. The present invention provides: a compound represented by formula ...
|
|
WO/2014/108629A1 |
The invention relates to a compound having general formula (I) and the pharmaceutically acceptable salt thereof, and to the use of said compound for cosmetic or pharmaceutical uses.
|
|
WO/2014/104090A1 |
The present invention provides an energy-sensitive resin composition, a method for manufacturing a polyimide film or a polyimide compact in which said composition is used, and a method for forming a pattern in which said composition is u...
|
|
WO/2014/100438A1 |
The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and Ra are as described herein. The present invention relates generally to selective inhib...
|
|
WO/2014/090716A1 |
The invention relates to a thiol-functional organic compound having on average at least 3.1 thiol groups per molecule, and having carbon atoms, oxygen atoms, and sulfur atoms, and optionally further heteroatoms, and wherein the ratio of ...
|
|
WO/2014/090913A1 |
The invention relates to a new method for producing bis(3-aminophenyl)disulfides of general formula (I) and 3-aminothiols of general formula (II), wherein X and Y have the meanings specified in the description, which are used as intermed...
|
|
WO/2014/090766A1 |
The invention relates to a method for producing 4-haloalkyl -3-mercapto-substituted 2-hydroxy-benzoic acid derivatives of general formula (I) by reacting 4-thio-substituted ß-ketoesters of formula (II) with alkoxyvinylhaloalkyl ketones ...
|
|
WO/2014/082737A1 |
The invention relates to specific carboxamides of formula (I) as KCNQ2/3 modulators, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.
|
|
WO/2014/079398A1 |
The present invention relates to the technical field of chemically synthesized drugs, in particular to an anti-HIV drug or prodrug and preparation method and uses thereof. The compound or prodrug compound of the present invention has a s...
|
|
WO/2014/072995A2 |
This invention discloses aromatic based sulfur containing hydrophobic acrylate monomer with high refractive index. The invention further discloses process for the preparation of 2-phenyl-2-(phenylthio)ethyl acrylate of the formula (I). T...
|
|
WO/2014/067940A1 |
The invention relates to polysulfide mixtures containing two or more compounds of the formula (I) in which the cations K1 + and K2 + independently of each other represent any monovalent cation or the n-th part of an n-valent cation and m...
|
|
WO/2014/069555A1 |
Provided is a compound that exhibits an excellent melanogenesis-inhibiting effect (skin-lightening effect), exhibits an excellent antimicrobial effect, excels in terms of temporal stability and the like, and is suitable for use as an ing...
|
|
WO/2014/065215A1 |
The present invention addresses the problem of providing: a transparent electrode provided with conductivity and light transmissivity, having low sheet resistance, and exhibiting excellent durability; and an electronic device and an orga...
|
|
WO/2014/064162A1 |
Neprilysin inhibitors are described. The compounds or compositions containing them can be used as antidiarrheal agents, antisecretory agents, anxiolytic agents, antidepressants, cicatrizants, fluid effusion reducers or in the treatment o...
|
|
WO/2014/064077A1 |
The present invention relates to a new crystalline phase of (3S,3S') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation the...
|
|
WO/2014/063968A1 |
The invention relates to a sulphuretted polyaromatic polyamine that can be used as a monomer or prepolymer when n is different from zero, for the synthesis of polyurea, said compound satisfying formula (I): H2N−Ar1−NH−CH2−CH(OH)â...
|
|
WO/2014/062221A1 |
The invention provides compounds of the Formula (I), methods of making the compounds, and devices comprising the compounds.
|
|
WO/2014/062044A1 |
Invention is related to novel compounds - fluorinated benzenesulfonamides of general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participa...
|
|
WO/2014/056939A1 |
The present invention relates to novel compounds, particularly for use as additives in a lipidic cubic phase material, and to novel lipidic cubic phase materials. These materials are biocompatible, stable and transparent and can encapsul...
|
|
WO/2014/053694A1 |
Compounds of formula I, wherein A, B, X, Z and R1-R6, are as defined in the claims, exhibit TRPA 1 activity and are thus useful as TRPA1 modulators.
|
|
WO/2014/044514A1 |
The present invention relates to polysulphides of the formula (I), wherein the cations K1 + and K2 + are independent of one another for any monovalent cation or for the fraction of a cation of any valency that corresponds to a positive c...
|
